Search

826 Result(s)
Sort by

A Unique Bond: there’s nothing like it

A Unique Bond: there’s nothing like it

It's not easy to live with systemic sclerosis, but the remarkable relationship Anna has built with Csenge has helped her realise her capabilities.
Immuno-Oncology

Immuno-Oncology

We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Difficulties Chewing and Swallowing

Difficulties Chewing and Swallowing

Discover tips on how to overcome difficulties in chewing and swallowing food from Taking Cancer On Through Flavour
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Saving Lives

Saving Lives

The Angels initiative honours nurses saving lives one grandpa at a time
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease